Want to see CSBR full AI Analyst Report?
Top Page
Champions Oncology
(NASDAQ:CSBR)
Select Model
Select Model
Rating:46Neutral
Price Target:
$5.50
▼(-10.28% Downside)
Action:Reiterated
Date:07/29/26
The score is held down primarily by highly unstable financial performance and cash flow (sharp FY2026 deterioration after FY2025 strength) and a bearish technical trend with the stock below major moving averages. These are partially offset by a somewhat constructive earnings call outlook (guidance for full-year revenue growth and positive adjusted EBITDA, plus early data-deal traction), while valuation is not clearly supportive due to the negative P/E and lack of dividend yield.
Positive Factors
Core Services Revenue Growth
Sustained, double-digit growth in core study revenue reflects durable demand for Champions' fee-for-service oncology models. Strong backlog conversion and repeat customer study execution support predictable medium-term service revenue and improve prospects for steady cash generation as scale persists.
Negative Factors
Volatile Cash Generation
A sharp flip from positive to negative cash flow demonstrates inconsistent conversion of revenue into cash. This volatility increases the probability of external financing needs, complicates multi‑period planning, and makes the company more vulnerable to timing swings in study completions and client payments.
Read all positive and negative factors
Positive Factors
Negative Factors
Core Services Revenue Growth
Sustained, double-digit growth in core study revenue reflects durable demand for Champions' fee-for-service oncology models. Strong backlog conversion and repeat customer study execution support predictable medium-term service revenue and improve prospects for steady cash generation as scale persists.
Read all positive factors
Champions Oncology Key Performance Indicators (KPIs)
Any
Revenue By Segment
Breaks down revenue by different business segments, highlighting which areas are driving growth and profitability. This can indicate strategic focus and potential areas for expansion or risk.
Breaks down revenue by different business segments, highlighting which areas are driving growth and profitability. This can indicate strategic focus and potential areas for expansion or risk.
Data provided by:
The Fly
The FlyChampions Oncology (CSBR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$74.47M
Dividend YieldN/A
Average Volume (3M)17.98K
Price to Earnings (P/E)―
Beta (1Y)0.40
Revenue Growth4.36%
EPS Growth-123.29%
CountryUS
Employees213
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.08
Shares Outstanding13,893,569
10 Day Avg. Volume35,034
30 Day Avg. Volume17,980
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)20.93
Price to Sales (P/S)1.39
P/FCF Ratio-16.37
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.1
Revenue Forecast (FY)$65.26M
Champions Oncology Business Overview & Revenue Model
Company Description
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the hea...
How the Company Makes Money
Champions Oncology primarily makes money by delivering fee-for-service research and development support to biopharmaceutical companies and other research organizations developing cancer therapeutics. Revenue is generated from contracted services t...
Champions Oncology Earnings Call Summary
Earnings Call Date:Mar 12, 2026
(Q3-2026)
| % Change Since: |
Next Earnings Date:Sep 16, 2026
Earnings Call Sentiment Positive
The call conveyed solid operational execution — record services revenue, ~32% growth in core study revenue, and a third consecutive positive adjusted EBITDA — alongside deliberate investments in data and a therapeutic subsidiary (Corellia). However, near-term challenges include a modest overall revenue decline (~3%) driven by absence of prior-year data license revenue, compression of gross margin (61% to 47%) driven in part by outsourced radiolabeling costs, and elevated operating expenses (~+36%). Data revenue remains early and variable, and Corellia funding timing is uncertain. On balance, the positive operational momentum and pathway to monetize data and Corellia slightly outweigh the near-term margin and timing headwinds.Positive Updates
Record Services Revenue and Core Study Growth
Total revenue of $16.6M for the quarter with core study (services) revenue a record $16.6M, up from $12.6M year-ago (~+32%), reflecting strong study execution and conversion of previously booked work.
Negative Updates
Overall Revenue Slight Decline Year-Over-Year
Total revenue declined to $16.6M from $17.0M year-ago (~-3%), primarily due to recognition of $4.5M of data revenue in the prior-year quarter that was not recognized this quarter.
Read all updates
Q3-2026 Updates
Positive
Negative
Record Services Revenue and Core Study Growth
Total revenue of $16.6M for the quarter with core study (services) revenue a record $16.6M, up from $12.6M year-ago (~+32%), reflecting strong study execution and conversion of previously booked work.
Read all positive updates
Company Guidance
The company guided that it remains on track for full‑year revenue growth and full‑year positive adjusted EBITDA, expects to close additional data revenue in Q4 (including a closed 6‑figure data deal and incremental revenue from the large data deal announced in Q3 FY25), and sees the payoff from current investments beginning in fiscal 2027 with more meaningful acceleration in fiscal 2028; Corellia funding is included in initial fiscal 2027 budgets (though external financing could redeploy that EBITDA). For context, Q3 results underpinning the guidance included total revenue of $16.6M (down ~3% YoY from $17.0M) driven by record study revenue of $16.6M (+~32% YoY vs $12.6M) and no data revenue this quarter (vs $4.5M prior), adjusted EBITDA of $575K (GAAP loss from operations ≈$275K), gross margin of 47% ($8.8M cost of sales, >$2M of which was outsourced lab work — if performed internally margin would exceed 50%), operating expenses of $7.2M (vs $5.3M), net cash used in operations $1.4M, and $7.1M cash with no debt.Champions Oncology Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
38
Negative
Cash Flow
31
Negative
| Breakdown | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 59.42M | 56.94M | 50.16M | 53.87M | 49.11M |
| Gross Profit | 28.52M | 28.55M | 20.75M | 24.34M | 25.48M |
| EBITDA | 448.00K | 6.27M | -5.44M | -3.02M | 2.21M |
| Net Income | -1.18M | 4.70M | -7.28M | -5.33M | 548.00K |
Balance Sheet | |||||
| Total Assets | 26.99M | 32.34M | 26.13M | 34.31M | 35.38M |
| Cash, Cash Equivalents and Short-Term Investments | 4.87M | 9.79M | 2.62M | 10.12M | 9.01M |
| Total Debt | 4.59M | 6.11M | 7.43M | 8.60M | 9.47M |
| Total Liabilities | 22.92M | 28.57M | 28.04M | 29.68M | 26.28M |
| Stockholders Equity | 3.94M | 3.77M | -1.90M | 4.64M | 9.10M |
Cash Flow | |||||
| Free Cash Flow | -5.04M | 7.00M | -6.97M | 1.08M | 4.11M |
| Operating Cash Flow | -4.47M | 7.39M | -6.14M | 3.96M | 6.50M |
| Investing Cash Flow | -540.00K | -389.00K | -836.00K | -2.87M | -2.38M |
| Financing Cash Flow | 99.00K | 170.00K | -527.00K | 11.00K | 207.00K |
Champions Oncology Technical Analysis
Negative
6.13
Price Trends
5.98
Negative
5.97
Negative
6.29
Negative
Market Momentum
-0.15
Positive
36.74
Neutral
7.29
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CSBR, the sentiment is Negative. The current price of 6.13 is above the 20-day moving average (MA) of 5.84, above the 50-day MA of 5.98, and below the 200-day MA of 6.29, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 36.74 is Neutral, neither overbought nor oversold. The STOCH value of 7.29 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CSBR.
Champions Oncology Risk Analysis
Champions Oncology disclosed 30 risk factors in its most recent earnings report. Champions Oncology reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Champions Oncology Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $112.48M | -2.81 | -22.03% | ― | -14.30% | 7.54% | |
52 Neutral | $33.56M | -1.81 | -198.35% | ― | ― | 21.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $74.47M | -67.00 | -28.00% | ― | 4.36% | -123.29% | |
46 Neutral | $96.84M | -2.22 | -36.37% | ― | -100.00% | -1056.82% | |
45 Neutral | $65.93M | -1.28 | -95.50% | ― | -10.71% | 28.59% | |
43 Neutral | $89.91M | -3.14 | 5214.36% | ― | ― | 13.21% |
* Healthcare Sector Average
CSBR
Champions Oncology
5.36
-1.02
-15.99%
ONCY
Oncolytics Biotech
0.75
-0.13
-14.72%
CRDF
Cardiff Oncology
0.86
-1.65
-65.94%
MXCT
MaxCyte
1.05
-1.03
-49.52%
BDTX
Black Diamond Therapeutics
1.69
-1.14
-40.28%
LTRN
Lantern Pharma
2.63
-2.69
-50.56%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.